NVRO Earnings Prediction
The chart below shows how NVRO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NVRO sees a +5.12% change in stock price 10 days leading up to the earnings, and a -9.19% change 10 days following the report. On the earnings day itself, the stock moves by +0.86%. This data can give you a slight idea of what to expect for the next quarter's release.
NVRO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
96.91M
-6.69%
-6.96%
Gross Margin
65.91%
-1.52%
2.89%
Operating Margin
-15.66%
-36.37%
-32.50%
Net Margin
-15.83%
-29.99%
-15.75%
EPS
-0.41
-36.92%
-22.64%
No Data Available
NVRO Earnings Analysis
NEVRO CORP. Corporation (NVRO.N) Earnings Conference Call
Positive
Global Revenue Decline: World wide revenue of $96.9 million decreased 6.7% on a reported basis and U.S. revenue of $83.9 million decreased 6.5%.
Improved Operational Losses: Net loss from operations was $13.9 million compared with $25.6 million in the year ago quarter, and adjusted EBITDA was negative $1.8 million compared with a loss of $5.8 million in the year ago quarter, reflecting the actions we took through our restructuring earlier this year and our focus on expense management as we drive toward profitability.
Cash and Investments Increase: Cash, cash equivalents and short-term investments increased $3.3 million to $277 million as of September 30, 2024, from June 30, 2024. This increase reflects the benefits from our restructuring in the first half of this year and strong working capital management.
Cash Position Improvement: We expect our cash position to increase further in the fourth quarter.
2024 Revenue Guidance Update: We are maintaining our fully year 2024 world wide revenue guidance of approximately $400 million to $405 million, representing an approximately 5% to 6% decrease from our 2023 world wide revenue on both a reported and constant currency basis.
Negative
Global Revenue Decline: World wide revenue of $96.9 million decreased 6.7% on a reported basis and U.S. revenue of $83.9 million decreased 6.5%.
Decline in SCS Procedures: U.S. spinal cord stimulation or SCS trial procedures declined approximately 15.2%.
Improved Operational Losses: Net loss from operations was $13.9 million compared with $25.6 million in the year ago quarter, and adjusted EBITDA was negative $1.8 million compared with a loss of $5.8 million in the year ago quarter.
International Revenue Decline: International revenue of $13 million decreased 7.7% as reported and 9.6% on a constant currency basis.
Market Penetration Insights: The PDN market remains underpenetrated at less than 1%.
NVRO FAQs
How does NVRO typically perform around its earnings report dates?
Is Nevro Corp. (NVRO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NVRO Earning Call Sentiment
Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NVRO.N
-0.35%Positive
The earnings call reveals several negative indicators: declining revenue and trials in the core SCS market, negative adjusted EBITDA, and reduced 2024 revenue guidance. Despite restructuring efforts and a slight cash increase, competitive pressures persist. The Q&A section highlights management's focus on cost-cutting and strategic investments, but lacks clear quantitative guidance and timelines for improvement. The negative sentiment is reinforced by the weak financial performance and cautious market outlook, suggesting a negative stock price movement of -2% to -8% over the next two weeks.
